LIMR Chemical Genomics Center

Contact Mel Reichman PhD at 484.476.8230

Impact Opportunities LCGC Offers You

- Deliver critical new leads data 5-times faster and 5-times less expensively.
- Curate your compounds, RNA/DNA and reagents in our innovative repository., while lowering costs.
- Unify multi-site chemical and bio libraries for ultra-rapid retrieval and distribution.
- Reinvigorate stymied projects to find new leads. Interrogate new scaffolds.
- Provide a totally new, six-sigma front-end for SOA research assets management.
- Format large compound libraries—from neat powders to candidate nomination.
- Accelerate and enhance data quality for focused SAR on-the-fly.
- Collaborate to illuminate cell-signaling networks that respond synergistically.
- Enable JIT data for grants, BOD reports, conferences and enticing VCs.
- Transform the drug discovery landscape by bridging public and private research domains.

Our Approach

New chemical diversity is immediately available in LCGC's assay-ready **Orthogonal-Pooled Screening (OPSTM) format**. The majority of LCGC's library is unique compared with those widely available, and almost all the **compounds were rigorously filtered** to eliminate undesirable features.



1.The LCGC library is **biased to lead-likeness.** Many of the compounds are appropriate for fragment-based HTS. You can also see LCGC library (red) compared to NIH SMLR library (blue)

2. Assay-ready, orthogonally pooled screening plates that allow **500% more efficient HTS are made available at low cost.** In biochemical assays (4), average HTS activity confirmation is 72%. In cellular assays (4), average HTS activity confirmation is 95%.

3. Our approach **may detect hidden mechanisms** of action and interactions between signaling pathways, while ensuring assay validity and efficient target and lead prioritization.



4. LCGC has validated **a new, high-capacity (10M samples) storage and distribution center** for public and private chemical collections.



5. **Importantly, the IP of all parties is totally protected**, while allowing joint research to occur efficiently.

We want to help universities and pharmaceutical companies to discover and develop new medicines by accelerating the validation of IP with important medicinal utilities.